OncLive SOSS

Authors

Pierre Gholam, MD, UH Westlake Health Center

Latest:

Hepatocellular Carcinoma: A Rapidly Evolving Treatment Landscape

Discussion around topics pertaining to the use of systemic therapy in advanced liver cancer. Topics will include the latest research in the field and the impact of recent clinical trials on making decisions around treatment selection.

Pieter Sonneveld, MD, PhD

Latest:

Dr Sonneveld on the Background of the D-VRd Regimen in Newly Diagnosed Myeloma

Pieter Sonneveld, MD, PhD, discusses the background of the PERSEUS trial, which evaluated D-VRd for induction and consolidation in newly diagnosed myeloma.

Pieternella J. Lugtenburg, MD, PhD

Latest:

Dr. Lugtenburg on Maintenance Rituximab in DLBCL

Pieternella J. Lugtenburg, MD, PhD, an internist and hematologist at Erasmus Medical Center in Rottenham, Netherlands, discusses the use of rituximab as maintenance therapy in patients with diffuse large B-cell lymphoma.

Pinkal Desai, MD, MPH

Polly Mazanec, PhD, ACNP, AOCN, FPCNÂ

Latest:

Managing Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy is a common side effect in patients with cancer and nurses are essential to helping patients to manage this condition.

Pooja Murthy, MD

Latest:

Integrating PARP Inhibitors Into the Treatment of Women

After years in development, several PARP inhibitors have achieved indications in ovarian cancer treatment, while others continue in development and expanding indications.

Prachi Patel-Predd

Latest:

News Reports: April 2007

News reports featured in this issue: 1) Breast Cancer Spotlight 2) Expert Cancer Centers Cost-Effective for Managing Ovarian Cancer 3) New Breathalyzer

Prajnan Das, MD, MPH

Latest:

Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer

An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.

Pramod K. Mistry, MD, PhD

Latest:

Dr. Mistry on Gaucher Disease Entering a New Era

Dr. Pramod Mistry from Yale University School of Medicine on Gaucher Disease Entering a New Era

Prapti Patel, MD

Latest:

Dr. Patel on the Clinical Implications of Luspatercept Approval in MDS

Prapti Patel, MD, discusses the clinical implications of the FDA approval of luspatercept-aamt in myelodysplastic syndrome.

Prasad S. Adusumilli, MD

Latest:

Dr. Adusumilli on the Rationale for Mesothelin-Targeted CAR T-Cell Therapy

Prasad S. Adusumilli, MD, surgeon, deputy chief of Thoracic Service, co-director of the Mesothelioma Program, head of Solid Tumors Cell Therapy, Cellular Therapeutics Center, at Memorial Sloan Kettering Cancer Center, discusses the rationale for an autologous mesothelin-targeted CAR T-cell therapy in advanced solid tumors.

Prasad S. Adusumilli, MD, FACS

Latest:

Dr. Adusumilli on the Development of CAR T Cells in Solid Tumors

Prasad S. Adusumilli, MD, FACS, discusses the current role of chimeric antigen receptor T-cell therapy as treatment of patients with solid tumors and how this is evolving compared to CAR T cells in hematologic malignancies.

Prashant Kapoor, MD

Latest:

Dr. Kapoor on Advice for Oncologists Treating Patients With Myeloma

Prashant Kapoor, MD, hematologic oncologist, Mayo Clinic, shares advice for community oncologists who are treating patients with multiple myeloma.

Praveen Ramakrishnan, MD

Latest:

Dr. Ramakrishnan on Negative Results of the BELINDA Trial in Non-Hodgkin Lymphoma

Praveen Ramakrishnan, MD, discusses the negative results from the phase 3 BELINDA trial and its effect on the use of CAR T-cell products in aggressive B-cell non-Hodgkin lymphoma.

Preet M. Chaudhary, MD, PhD

Latest:

Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD

Discussion centered around real-world data following the approval of ruxolitinib as a treatment option for patients with chronic GvHD as well as discussing treatment selection for patients with chronic GvHD, with special consideration for treatment sequencing.

Preetesh Jain, MD, PhD

Latest:

Rapid Readouts: Ibrutinib Plus Rituximab and Venetoclax Followed by Risk-Stratified Chemoimmunotherapy in Young Patients With Previously Untreated MCL

Expert perspectives on the phase II clinical trial assessing IRV triplet therapy in young patients with previously untreated mantle cell lymphoma to help minimize chemotherapy exposure.

Premal H. Thaker, MD, MS

Latest:

Relacorilant Plus Nab-Paclitaxel Carves New Avenues of Platinum-Resistant Ovarian Cancer Care: With Premal Thaker, MD, MS

Dr Thaker discusses the rationale for combining relacorilant with nab-paclitaxel in platinum-resistant ovarian cancer, and the future of the ROSELLA trial.

Premal Lulla, MD

Latest:

Dr. Lulla Discusses Post-Transplant Options for Leukemias

Premal Lulla, MD, discusses the need for cellular therapies for patients with leukemia after transplant.

Prerna Mewawalla, MD

Latest:

Smart Apps for Smart Docs

Life as a fellow is extremely hectic, and mobile apps can help us save an enormous amount of time when conducting research.

Prescott Deininger, PhD

Latest:

Dr. Deininger on the Role of Genetic Instability in Mutations That Lead to Cancer

Prescott Deininger, PhD, Professor and Regents Distinguished Chair, director, Tulane Cancer Center, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, discusses how genetic instability plays a role in mutations that may lead to specific tumor types.